Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.

作者信息

Podar K, Tai Y T, Davies F E, Lentzsch S, Sattler M, Hideshima T, Lin B K, Gupta D, Shima Y, Chauhan D, Mitsiades C, Raje N, Richardson P, Anderson K C

机构信息

Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.

出版信息

Blood. 2001 Jul 15;98(2):428-35. doi: 10.1182/blood.v98.2.428.

Multiple myeloma (MM) remains incurable, with a median survival of 3 to 4 years. This study shows direct effects of vascular endothelial growth factor (VEGF) upon MM and plasma cell leukemia (PCL) cells. The results indicate that VEGF triggers tumor cell proliferation via a protein kinase C (PKC)-independent Raf-1-MEK-extracellular signal-regulated protein kinase pathway, and migration via a PKC-dependent pathway. These observations provide the framework for novel therapeutic strategies targeting VEGF signaling cascades in MM.